en · de · es · fr · pt
compound-index.peptides9002.com › Blog › Background And Mechanism Of Melanotan-2 — Questions and Answers

Background And Mechanism Of Melanotan-2 — Questions and Answers

By Editorial Desk · published 2026-07-13 · last reviewed 2026-08-01 · Blog

melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.

Chemical Background and Receptor Activity

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Melanotan-2 at a glance

PropertyValueNotes
Compound classSynthetic cyclic heptapeptideAlpha-MSH analogue containing a D-phenylalanine residue
Molecular formulaC50H69N15O9Average molecular mass approximately 1024.2 g/mol
AppearanceWhite to off-white lyophilised powderNormally supplied as a freeze-dried solid in a sealed vial
SolubilityFreely soluble in water and polar solventsDissolves readily in aqueous buffers and in alcohol-water mixtures
Receptor targetsMC1R, MC3R, MC4R, MC5RActs as a non-selective melanocortin receptor agonist

Identity and Chemical Background

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Related pages on this site

Background and Chemical Profile

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Notes from published material

Wanted immunogenicity typically relates to vaccines, where the injection of an antigen (the vaccine) provokes an immune response against the pathogen, protecting the organism from future exposure. Immunogenicity is a central aspect of vaccine development. Unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug-antibodies (ADAs), inactivating the therapeutic effects of the treatment and potentially inducing adverse effects. A challenge in biotherapy is predicting the immunogenic potential of novel protein therapeutics. For example, immunogenicity data from high-income countries are not always transferable to low-income and middle-income countries. Another challenge is considering how the immunogenicity of vaccines changes with age. Therefore, as stated by the World Health Organization, immunogenicity should be investigated in a target population since animal testing and in vitro models cannot precisely predict immune response in humans. Antigenicity is the capacity of a chemical structure (either an antigen or hapten) to bind specifically with a group of certain products that have adaptive immunity: T cell receptors or antibodies (a.k.a. B cell receptors). Antigenicity was more commonly used in the past to refer to what is now known as immunogenicity, and the two terms are still often used interchangeably. However, strictly speaking, immunogenicity refers to the ability of an antigen to induce an adaptive immune response.

The fifth season of the American television drama series Scandal was ordered on May 7, 2015, by ABC, and began airing on September 24, 2015, in the United States on ABC. The season was produced by ABC Studios, in association with ShondaLand Production Company; the showrunner being Shonda Rhimes. The season continues the story of Olivia Pope's crisis management firm, Olivia Pope & Associates, and its staff, as well as staff at the White House in Washington, D.C. Season five has eleven series regulars, all returning from the previous season, out of which six are part of the original cast of eight regulars from the first season and three new regulars were added. The season will continue to air in the Thursday 9:00 pm timeslot, the same as the previous season as it was moved to make room for ShondaLand Production Company's new TV series, How to Get Away with Murder. On March 3, 2016, ABC announced that Scandal was renewed for a sixth season.

== Alternative Structural Classification == Many phosphatases are promiscuous with respect to substrate type, or can evolve quickly to change substrate. An alternative structural classification notes that 20 distinct protein folds have phosphatase activity, and 10 of these contain protein phosphatases.

Moreover, mining hardware's short lifespan results in electronic waste. In October 2025, the US was the largest mining country with 38% of the global bitcoin mining market share, followed by Russia (16%) and China (14%, despite all cryptocurrency trading and mining being banned there in 2021).

Sources: en.wikipedia.org

Further detail

=== Prohibited content === Facepunch Studios blacklists servers that are malicious, depict sexual violence, or contain content that is not safe for work but not marked as such. In April 2023, following a Twitter poll with close to 50,000 respondents, the company additionally banned the glorification of Nazism, including the display of swastikas and the Nazi salute.

In 2015, filgrastim was included on the WHO Model List of Essential Medicines, a list containing the medications considered to be most effective and safe to meet the most important needs in a health system.

Focke-Wulf A 3 Focke-Wulf A 4 Focke-Wulf A 5 Focke-Wulf A 6 Focke-Wulf A 7 Focke-Wulf A 16 – light transport aircraft, 1924. First design built by Focke-Wulf. Focke-Wulf A 17 Möwe (Gull) – 8-passenger airliner, 1927. Focke-Wulf A 20 Habicht (Hawk) – 4-passenger feederliner, 1927. Focke-Wulf A 21 Photomöwe – aerial photography version of A 17, 1929. Focke-Wulf A 26 – engine testbed Focke-Wulf A 28 – A 20 with Bristol Titan engine Focke-Wulf A 29 – production version of A 17, 1929. Focke-Wulf A 32 Bussard (Buzzard) – airliner, 1930. Focke-Wulf A 33 Sperber (Sparrowhawk) – 3-passenger airliner, 1930. Focke-Wulf A 36 Mastgans (Mast Goose) – mail plane, 1931. Focke-Wulf A 38 Möwe (Gull) – 10-passenger airliner, 1931. Focke-Wulf F 19 Ente (Duck) – experimental civil utility aircraft, 1927. Focke-Wulf GL 18 – light transport aircraft developed from the A 16, 1926. Focke-Wulf GL 22 – revised GL 18, 1927. Focke-Wulf K 23 Buchfink (Chaffinch) – two-seat reconnaissance aircraft, 1928. Focke-Wulf AL 101 D Albatros Focke-Wulf S 1 – trainer, 1925. Focke-Wulf S 2 – two-seat trainer, 1928. Focke-Wulf S 24 Kiebitz (Lapwing) – two-seat sports biplane, 1928. Focke-Wulf S 39 – two-seat reconnaissance parasol monoplane, 1931-1932. Focke-Wulf W 4 – reconnaissance floatplane, 1927. Focke-Wulf W 7 – maritime patrol biplane, 1932.

Pd complexes of JohnPhos catalyze Suzuki-Miyaura reactions with aryl bromides and chlorides. It tolerates hindered substrates and operates at room temperature with low catalyst loading. This ligand has been utilized in multiple reactions including the amination of a range of aryl halides and triflates as well as the arylation of thiophenes.

2024 United Kingdom riots: Two 12-year-old boys become the youngest people to be convicted following their involvement in the disorder. Figures show that 125 migrants crossed the English Channel in small boats. 13 August Banknotes featuring King Charles, with a face value of £78,430 and low serial numbers, are auctioned for £914,127 to raise money for charity. An inquest is held into the death of former England cricketer Graham Thorpe, who died from suicide after being struck by a train at a railway station. Data from the Office for National Statistics shows UK unemployment fell to 4.2% in the three months to June, down from 4.4% during the previous quarter. Ofgem approves a £3.4bn project for a subsea cable allowing renewable energy to be transported from Scotland to England more easily. 14 August Inflation is reported to have risen from 2% to 2.2%, the first increase during 2024. The predicted increase is largely a result of a smaller fall in gas and electricity prices in July when compared to July 2023. 2024 United Kingdom riots: A 53-year-old woman from Cheshire is sentenced to 15 months in prison after admitting sending a communication threatening death or serious harm over a Facebook post in which she suggested a mosque should "be blown up with the adults inside". Two men found in a burned-out car in Malmö, Sweden, are confirmed as two British men, Farooq Abdulrazak, 37, and Juan Cifuentes, 33, who went missing in July. Train drivers' union ASLEF is to ballot its members on a revised pay offer following negotiations with the Department for Transport.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Has it been approved for any medical use?

No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.

Which receptor matters most for pigmentation?

Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network